文献速递乳腺癌支持与姑息治疗

老年HER2阳性乳腺癌患者曲妥珠单抗单药与联合化疗的生活质量对比

Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
PubMed 文献 · J Clin Oncol · 2021-04-09

RESPECT试验比较了70-80岁HER2阳性乳腺癌术后患者接受曲妥珠单抗单药(T)或曲妥珠单抗联合化疗(T+C)的生活质量。共231例(平均74岁)纳入分析,T组在2个月和12个月时生活质量恶化比例显著低于T+C组,但36个月时各组无显著差异;化疗对整体生活质量、士气和活动能力的负面影响至少持续12个月。

要点

  • T组2个月和12个月生活质量恶化比例显著低于T+C组。
  • T组2个月焦虑抑郁评分和严重感觉周围神经病变比例更低。
  • 36个月时两组所有生活质量项目无显著差异。

核心结论

  • 辅助化疗对老年HER2阳性乳腺癌患者整体生活质量、士气和活动能力的负面影响至少持续12个月,但36个月时未观察到。

研究设计与样本

  • RESPECT试验为随机对照研究,纳入70-80岁HER2阳性术后乳腺癌患者,随机接受曲妥珠单抗(T)或曲妥珠单抗联合化疗(T+C)。
  • 生活质量分析纳入231例(84%),平均年龄74岁,使用FACT-G、PGC Morale Scale、HADS、PNQ和TMIG-IC在基线及2、12、36个月评估。

主要发现

  • 36个月时所有生活质量项目两组无显著差异。

临床怎么用

  • 对于70-80岁HER2阳性乳腺癌术后患者,曲妥珠单抗单药相比联合化疗可减少至少12个月内的生活质量恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report findings on quality of life (QoL) in the RESPECT trial, which compared adjuvant trastuzumab monotherapy with trastuzumab plus chemotherapy in older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). PATIENTS AND METHODS: Patients age 70-80 years with human epidermal growth factor receptor 2-positive surgically treated breast cancer were randomly assigned to receive trastuzumab (T) or trastuzumab plus chemotherapy (T + C). QoL was assessed using the Functional Assessment of Cancer Therapy-General (FACT-G), Philadelphia Geriatric Center Morale Scale, Hospital Anxiety and Depression Scale, Patient Neurotoxicity Questionnaire, and Tokyo Metropolitan Institute of Gerontology Index of Competence at baseline and after 2, 12, and 36 months. Comparisons were based on individual changes from baseline and were performed by Fisher's test or mixed-model repeated-measures. RESULTS: Among 275 patients in the parent study, 231 (84%) (average age: 74 years) were included in the analysis. At 2, 12, and 36 months, 198, 177, and 178 patients completed surveys, and the mean FACT-G scores at each survey point were 78.9, 80.4, 82.7, and 79.1 in group T and 79.5, 74.5, 78.4, and 78.5 in group T + C. Compared with group T + C, the proportion of patients showing QoL deterioration (≥ 5 points decrease from baseline in FACT-G) was significantly lower at 2 months (31% v 48%; P = .016) and 12 months (19% v 38%; P = .009). In group T, the Hospital Anxiety and Depression Scale score (P = .003) and the proportion of severe sensory peripheral neuropathy (P = .001) were significantly lower at 2 months, and Philadelphia Geriatric Center Morale Scale and Tokyo Metropolitan Institute of Gerontology Index of Competence scores were significantly higher (P = .024, .042) at 12 months. At 36 months, there were no significant differences in any QoL items. CONCLUSION: Detrimental effects of adjuvant chemotherapy on global QoL, morale, and activity capacity lasted for at least 12 months but were not observed at 36 months.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Taira N, Sawaki M, Uemura Y, et al. Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. J Clin Oncol. 2021. PMID: 33835842. doi:10.1200/JCO.20.02751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。